Ceci Francesco, Herrmann Ken, Hadaschik Boris, Castellucci Paolo, Fanti Stefano
Nuclear Medicine Unit, S. Orsola-Malpighi University Hospital, University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy.
Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):78-83. doi: 10.1007/s00259-017-3723-3. Epub 2017 May 25.
While PET with non-FDG tracers (mainly choline and Ga-PSMA) has commonly been used for restaging in men with biochemically recurrent prostate cancer, as well as for primary staging, it is only recently that a few preliminary studies have addressed the possible use of PET for monitoring the response to systemic therapy of metastatic disease, especially innovative treatments such as abiraterone and enzalutamide. This article aims to evaluate the role of PET imaging with different non-FDG radiotracers for assessment of therapy in advanced prostate cancer patients.
虽然使用非氟代脱氧葡萄糖（FDG）示踪剂（主要是胆碱和镓-前列腺特异性膜抗原[Ga-PSMA]）的正电子发射断层扫描（PET）通常用于对生化复发前列腺癌男性患者进行再分期以及原发性分期，但直到最近才有一些初步研究探讨了PET在监测转移性疾病全身治疗反应，尤其是阿比特龙和恩杂鲁胺等创新治疗反应方面的可能用途。本文旨在评估使用不同非FDG放射性示踪剂的PET成像在评估晚期前列腺癌患者治疗中的作用。
